Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis-Reference-Cited by-同舟云学术

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis

Published:2018-02-13 Issue:2 Volume:24 Page:245-252
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Carcao M.¹^ORCID,Shapiro A.²,Staber J. M.³,Hwang N.⁴,Druzgal C.⁵,Lieuw K.⁶,Belletrutti M.⁷,Thornburg C. D.⁸,Ahuja S. P.⁹,Morales-Arias J.¹⁰,Dumont J.¹⁰,Miyasato G.¹¹,Tsao E.¹⁰,Jain N.¹⁰,Pipe S. W.¹²

Affiliation:

1. Division of Haematology/Oncology; Department of Paediatrics; Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children; Toronto ON Canada

2. Indiana Hemophilia & Thrombosis Center; Indianapolis IN USA

3. University of Iowa Stead Family Children's Hospital; Iowa City IA USA

4. Center for Inherited Blood Disorders; Orange CA USA

5. University of Virginia Health System; Charlottesville VA USA

6. Walter Reed National Military Medical Center; Bethesda MD USA

7. University of Alberta Stollery Children's Hospital; Edmonton AB Canada

8. Rady Children's Hospital San Diego; San Diego CA USA

9. University Hospitals Rainbow Babies and Children's Hospital; Cleveland OH USA

10. Bioverativ Therapeutics, Inc.; Waltham MA USA

11. Trinity Partners LLC; Waltham MA USA

12. University of Michigan; Ann Arbor MI USA

Funder